Corcept Therapeutics Case Study

An integrated approach to developing a promising candidate for the treatment of Cushing’s syndrome.

A case study on Quotient Sciences' accelerated approach to integrated clinical manufacturing and Phase 1 clinical trials

Corcept Therapeutics, based in California, USA, is a pharmaceutical company focused on the impact of cortisol on health and the development of glucocorticoid receptor (GR) antagonists. Following its foundation in 1998, the company successfully developed Korlym® (mifepristone), a dual GR and progesterone receptor (PR) antagonist for the treatment of endogenous Cushing’s syndrome (Hypercortisolism), a disorder associated with significant morbidity and mortality. However, the dual action of mifepristone limited the circumstances in which the drug can be used, and there was a need for a selective 'next generation' medication offering all of the benefits but without the associated risks.

Quotient Sciences were approached to help Corcept Therapeutics in their development of CORT125134. This was contracted out to us due to our ability to integrate clinical manufacturing and clinical trial dosing at the same location. Request a copy of our case study today and contact us to find out how we can accelerate drug development timelines saving as much as 12 months in the process with our Translational Pharmaceutics® platform.

Download our Corcept Therapeutics Case Study

Learn more about how Quotient Sciences' experts helped Corcept Therapeutics with our integrated clinical manufacturing and trial capabilities.

"The Phase I study of CORT125134 was contracted out to Quotient Sciences, largely due to the company’s ability to integrate manufacturing and dosing on the same site."

- Hazel Hunt, Chief Scientific Officer at Corcept Therapeutics

Global, integrated expertise. Local drug development partner.
Accelelerate Your Program